Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
PBGENE-DMD
product3 mentionslast seen Nov 9, 2026
Gene excision therapy for treatment of Duchenne muscular dystrophy.
Relationships 5
- Precision Biosciences, Inc.developsPBGENE-DMD99% confidence3 sources
- PBGENE-DMDapplies toDuchenne muscular dystrophy treatment95% confidence1 source
- PBGENE-DMDconforms toOrphan Drug designation95% confidence1 source
- PBGENE-DMDconforms toRare Pediatric Disease designation94% confidence1 source
- PBGENE-DMDdepends onARCUS85% confidence1 source
Relationship
Precision Biosciences, Inc.developsPBGENE-DMD
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGARNov 9, 2026PRECISION BIOSCIENCES INC 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
the Company projects it is sufficiently capitalized to fund both PBGENE-HBV and PBGENE-DMD clinical programs
- filingSEC EDGARNov 6, 2026PRECISION BIOSCIENCES INC 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Precision intends to use the net proceeds of the offering to fund the continued research and development of PBGENE-HBV and PBGENE-DMD
- filingSEC EDGARNov 5, 2026PRECISION BIOSCIENCES INC 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
PBGENE-DMD is Precision's clinical program for the treatment of DMD